HRS-4357 injection + Enzalutamide；Abiraterone
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Conditions
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Trial Timeline
Feb 2, 2026 → Dec 1, 2028
NCT ID
NCT07311694About HRS-4357 injection + Enzalutamide；Abiraterone
HRS-4357 injection + Enzalutamide；Abiraterone is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07311694. Target conditions include PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07311694 | Phase 3 | Recruiting |
Competing Products
1 competing product in PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AMO959 + Enzalutamide + Abiraterone | Novartis | Phase 1/2 | 41 |